Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: IPI stock price vs IDYA: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at IDYA's multiple
Needs IDYA P/E.
Implied fair value · at IPI's multiple
Needs Annual EPS is negative, IPI P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
INTREPID POTASH, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
IDEAYA Biosciences, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
MOSAIC CO
IPI vs MOS
Nutrien Ltd.
IPI vs NTR
COMPASS MINERALS INTERNATIONAL INC
IPI vs CMP
CVR PARTNERS, LP
IPI vs UAN
Archer-Daniels-Midland Co
IPI vs ADM
CF Industries Holdings, Inc.
IPI vs CF
Zentalis Pharmaceuticals, Inc.
IPI vs ZNTL
Blueprint Medicines Corp
IPI vs BPMC
Jazz Pharmaceuticals plc
IPI vs JAZZ
Sarepta Therapeutics, Inc.
IPI vs SRPT
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe IDYA’s extreme revenue growth will eventually convert into durable positive margins and justify a much higher sales multiple, then IDYA-based valuation argument would support owning IPI only with caution; otherwise, IPI looks more defensible on current fundamentals because it is already profitable, has better quality scores, and trades far below the IDYA-based implied value.
On the provided P/S basis, IPI trades at 1.5x versus IDYA at 15.1x, while EV/Revenue is 1.2x for IPI versus 12.5x for IDYA. That creates a massive implied price gap, but it is driven by very different business profiles: IPI is profitable today, whereas IDYA has negative margins and negative net income.
Supporting Metrics
